Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

Overview

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment

Full Title of Study: “A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 15, 2017

Detailed Description

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.

Interventions

  • Drug: Vinorelbine
    • Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
  • Drug: Letrozole
    • Lestrozole at 2,5 mg every day , per oral
  • Drug: Anastrozole
    • Anastrozole at 1 mg every day, per oral

Arms, Groups and Cohorts

  • Active Comparator: Vinorelbine
    • Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
  • Experimental: Vinorelbine+Anastrozole or Letrozole
    • Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity. And: Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity

Clinical Trial Outcome Measures

Primary Measures

  • Progression free survival (PFS)
    • Time Frame: up to 6 months
    • Proportion of progression or death

Secondary Measures

  • Evaluation of partial and complete response rate by RECIST 1.1
    • Time Frame: up to 6 months
    • partial and complete response rate by RECIST 1.1 in each arm
  • duration of response
    • Time Frame: up to 6 months
    • duration of response is defined as the time from randomization and the disease progression
  • clinical benefit after 24 weeks of treatment
    • Time Frame: up to 24 weeks
    • the clinical benefit is defined by the rate of complete response, by the rate of partial response and by the stability of lesions at 24 weeks according to criteria RECIST 1.1
  • overall survival
    • Time Frame: up to 2 years
    • the overall survival of patients randomized is defined as the time from randomization and the date of death
  • Toxicity according to criteria NCI CTAEv4.03
    • Time Frame: up to 2 years
    • tolerance of the treatment based on AE occurrence according to criteria NCI CTAEv4.03
  • health-related quality of life
    • Time Frame: up to 2 years
    • health-related quality of life and symptomatic state will be evaluated by filling a questionnaire by patients

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 50 years. 2. Histologically proven breast cancer. 3. Progesterone and /or oestrogene receptors positive. 4. HER2 negative on primary tumour. 5. Patient taking hormonotherapy, in progression, already treated by at least one line of anti-aromatase non-steroidal hormonotherapy and by at least on line of chemotherapy. 6. Patient having to begin a second or third line of chemotherapy. 7. Presence of one or several measurable(s) or assessable(s) metastatic lesion(s).In case of isolated bone lesion (s): need to have a non-irradiated with an osteolytic component for be considered as lesion (s) target (s) and having an elevation of the CA15-3. 8. Post menopausal woman. 9. ECOG 0, 1 or 2. 10. Adequate biological function.

  • Neutrophil ≥ 1,5.E9/L – Platelets ≥ 100.E9/L – Creatinine clearance ≥ 30 mL/min – Total bilirubin ≤ 1,5 x the upper limit of normal (ULN) – Alkaline phosphatase ≤ 2,5 x ULN – ALT, AST ≤ 1,5 x ULN in the absence of liver metastases or ≤ 3 x ULN if liver metastases. 11. Patient with a life expectancy greater than 3 months. 12. Signed informed consent before enrollment. 13. affiliation to a social security scheme Exclusion Criteria:

1. Patient with located or single metastatic tumoral relapse, accessible to a surgical treatment. 2. Patient having already received more 2 lines of chemotherapy for metastatic or advanced decease 3. Patient having already received a treatment by Navelbine® 4. Patient requiring an immediate located radiotherapy for analgesic action 5. Patient with non-irradiated cerebral or symptomatic metastasis, symptomatic pulmonary carcinomatosis lymphangitis 6. Simultaneous administration of another chemotherapy hormonotherapy or anti-tumoral drug 7. Patient having already received another treatment ongoing evaluation within the 30 days before the screening visit 8. Known positive serology HIV 9. Previous cancer within 5 years before the entry in the study, excepted an in situ carcinoma of the cervix or a spino or basal cell carcinoma of the skin or a nonmelanoma skin cancer with an adequate treatment. 10. Any serious concomitant pathology and / or uncontrolled could compromise participation in the study (including uncontrolled diabetes, uncontrolled hypertension, severe infection, profound malnutrition, unstable angina or congestive heart failure – class III or IV according to the New York Heart Association – ventricular arrhythmias, progressive coronary artery disease, myocardial infarction within the last six months, chronic liver or kidney disease, a progressive ulceration of the digestive tract above, CNS disorders). 11. Disorder of gastrointestinal function (GI) or pathology likely to significantly interfere with the absorption of Navelbine, of Letrozole or Anastrozole (eg. Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, syndrome malabsorption, or resection of the small intestine). 12. Known hypersensitivity to letrozole, anastrozole, vinorelbine or other vinco-alkaloids or any other component. 13. Patient with fructose intolerance, galactose, a Lapp lactase deficiency or malabsorption of glucose and galactose (rare hereditary disease). 14. Patient with a history of poor compliance with medical treatment. 15. Patient can not be monitored regularly for family reasons, geographical, social or psychological. 16. Patient with altered mental status would not allow him to understand the study or give informed consent .

Gender Eligibility: Female

Minimum Age: 50 Years

Maximum Age: 95 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ARCAGY/ GINECO GROUP
  • Collaborator
    • Pierre Fabre Laboratories
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pierre-Etienne HEUDEL, MD, Principal Investigator, Centre Leon Berard

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.